Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation in stable or post-exacerbation chronic obstructive.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.

The influence of noninvasive ventilation (NIV) on the delicate balance between increased load and decreased capacity of the respiratory system in severe.

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Consolidated Standards of Reporting Trials (CONSORT) diagram of patients enrolled in the study. #: Two pre-screen/screen failures were erroneously randomised,

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,

Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.

Survival without tracheostomy

Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.

Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. Examination of the prevalence.

Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.

Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (

Body mass index (BMI) among subjects with normal spirometry, chronic obstructive pulmonary disease (COPD) and restrictive spirometry. Body mass index (BMI)

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A white elephant or the elephant in the room

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Box-plot of alpha-diversity measured by wholetree phylogenetic differences grouped according to sampling method and chronic obstructive pulmonary disease.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

A–f) Respiratory mechanical measurements during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease (COPD) and age-matched.

Flow–volume loop analysis

a) Mortality per time point (p<0

Distribution of the differences in smallest worthwhile effects (SWEs) of land-based and water-based pulmonary rehabilitation on 6-min walk distance (in.

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Consolidated Standards of Reporting Trials diagram.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

Relationship between bronchodilator response of physiological parameters and concentration of interleukin (IL)-8 in epithelial lining fluid (ELF). Relationship.

Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.

NLRP3 inflammasome is activated during infectious exacerbations of chronic obstructive pulmonary disease (ECOPD). a) Protein concentration of caspase-1,

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Categorisation of social media posts related to chronic obstructive pulmonary disease (COPD). #: based on article ID, social media link and/or content.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

A) Forced expiratory volume in 1 s (FEV1) and b) 6-min walk test (6MWT) distance by bronchiectasis in any lobe/vascular pruning in the lower lobes groups.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Absolute change in forced expiratory volume in 1 s (FEV1) % pred over time in clinical trials with a) ivacaftor (IVA) in patients with at least one G551D.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Interleukin (IL)-1β and IL-18 in stable chronic obstructive pulmonary disease (COPD) patients. a) IL-1β and IL-18 relative transcript levels in lung tissues.

Comparison of exhaled H2O2 values in chronic obstructive pulmonary disease (COPD) patients (n=12) and control group (n=9). a) Raw ambient air concentrations.

Study design for ECLIPSE (VX-659 triple combination) and AURORA (VX-445 triple combination) phase 3 studies. Study design for ECLIPSE (VX-659 triple combination)

Comparison of pre- and post-bronchodilator data for spirometric and oscillometric parameters. Comparison of pre- and post-bronchodilator data for spirometric.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease severity (intent-to-treat population). Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease severity (intent-to-treat population). FF/UMEC/VI: fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg); BUD/FOR: budesonide/formoterol (400/12 µg). a) FEV1 % pred <50%, no moderate/severe exacerbations (n=626), b) FEV1 % pred <50%, ≥1 moderate/severe exacerbations (n=589) and c) FEV1 % pred 50– <80%, ≥2 moderate or ≥1 severe exacerbations (n=585). David M.G. Halpin et al. ERJ Open Res 2018;4:00119-2017 ©2018 by European Respiratory Society